Dr. D. Ross Camidge, MD, PhD, is a globally recognized thoracic oncologist and clinical researcher specializing in lung cancer. He serves as Director of Thoracic Oncology at the University of Colorado Cancer Center and holds the Joyce Zeff Chair in Lung Cancer Research. Dr. Camidge received his medical degree and doctorate from Oxford University in the United Kingdom and completed his postgraduate training in internal medicine and medical oncology at the Royal Marsden Hospital and the Royal Free Hospital. He is board-certified in Medical Oncology and has become a leading figure in the development of targeted therapies for non-small cell lung cancer (NSCLC).

A pioneer in precision oncology, Dr. Camidge was among the first to characterize and treat ALK-positive and ROS1-positive lung cancers with molecularly targeted therapies. His research has helped define resistance mechanisms to tyrosine kinase inhibitors and has guided the development of next-generation inhibitors. He has served as principal investigator in numerous pivotal clinical trials and is a frequent contributor to international guidelines on the treatment of advanced lung cancer. His work has reshaped how oncologists around the world approach biomarker-driven therapy and individualized treatment planning.

In addition to his groundbreaking research, Dr. Camidge is a respected educator and advocate for patient-centered care. He has published more than 300 peer-reviewed articles and has been recognized with numerous awards, including the Bonnie J. Addario Lectureship and ESMO Translational Research Award. He is known for his thoughtful communication style and strong patient advocacy, contributing to patient engagement initiatives and educational efforts for both clinicians and the public. Through his leadership in translational research and commitment to innovation, Dr. D. Ross Camidge continues to shape the global landscape of thoracic oncology.